(-)-Epigallocatechin Gallate sulfate (EGCG) 是绿茶中的一种主要多酚,可抑制细胞增殖并诱导细胞凋亡。 (-)-Epigallocatechin Gallate sulfate 可抑制谷氨酸脱氢酶 1/2 (GDH1/2, GLUD1/2) 的活性。(-)-Epigallocatechin Gallate sulfate 对结直肠癌、髓性白血病、甲状腺癌等多种癌症具有有效的抗癌、抗氧化和抗炎特性。
生物活性 | (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cellapoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectalcancer, myeloid leukemia, thyroid carcinoma[1][2][3][4]. |
IC50& Target[1] | |
体外研究 (In Vitro) | (-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner[1].(-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression[1].(-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration[1].(-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)[2].(-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase[3].(-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts[4].
Cell Proliferation Assay[1] Cell Line: | FB-2 and WRO cells (serum-starved for 48h) | Concentration: | 10, 40, 60 μM. | Incubation Time: | 4 days | Result: | Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM). |
Western Blot Analysis[1] Cell Line: | FB-2 cells | Concentration: | 10, 40, 60 μM. | Incubation Time: | 24 h | Result: | Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2.Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin. |
Cell Migration Assay[1] Cell Line: | FB-2 and WRO cells (serum-starved for 48h) | Concentration: | 10, 40, 60 μM. | Incubation Time: | 12 h | Result: | Reduced migration activity in FB-2 and WRO cells. |
RT-PCR[4] Cell Line: | Mouse primary osteoblasts (1 ng/ml LPS-treated) | Concentration: | 30 μM | Incubation Time: | 3, 6, 12, 24 h | Result: | Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production. |
|
体内研究 (In Vivo) | (-)-Epigallocatechin Gallate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth[3].(-)-Epigallocatechin Gallate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)[3].
Animal Model: | Orthotopic transplant BALB/c nude mice model[3] | Dosage: | 5, 10, and 20 mg/kg, once daily for 14 days. | Administration: | Intragastrical administration. | Result: | Inhibited tumors growth with no liver or lung metastases. |
Animal Model: | Model of experimental periodontitis, LPS (25 μg/mouse)[4] | Dosage: | 0.5 mg/mouse, a single dose. | Administration: | Injected into the mouse lower gingiva | Result: | Inhibited the LPS-induced loss of bone mineral density (BMD) in mice. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 30 mg/mL(65.45 mM) H2O : 20 mg/mL(43.63 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.1816 mL | 10.9082 mL | 21.8164 mL | 5 mM | 0.4363 mL | 2.1816 mL | 4.3633 mL | 10 mM | 0.2182 mL | 1.0908 mL | 2.1816 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 9.09 mg/mL (19.83 mM); Clear solution; Need ultrasonic and warming and heat to 60℃ 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.54 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.54 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.54 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|